Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application for Enhertu followed by paclitaxel, trastuzumab and pertuzumab has been accepted for review in the U.S. for the neoadjuvant treatment of adult patients with HER2 positive stage 2 or stage 3 breast cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- White House announces deal with Pfizer for ‘most-favored-nation pricing’
- AstraZeneca’s Tezepelumab Study: Real-World Insights on Asthma and Cough
- Trump says other drugmakers to join Pfizer with ‘most favored nation’ prices
- Fintech Giant Revolut Could Make History With Cross-Atlantic $75B IPO
- GlaxoSmithKline Stock (GSK) Up as CEO Emma Walmsley Steps Down for Luke Miels